2022 Medicare Part-D Plans in Massachusetts
There are 21 Medicare Part-D Plans available in Massachusetts from 8 different health insurance providers. You can choose from 3 prescription drug plans offering additional gap coverage. The plan with the lowest monthly premium is $7.40 and the highest monthly premium is $136.20. The highest rated Part-D plan available in Massachusetts County received a 4.5 overall star rating from the CMS and the lowest rated plan is 3 stars.
(Click the Plan Name for More Details)
(⇅ Click the Header to Sort)
Return 2022 Medicare Part D Plans
Medicare in Massachusetts, 2022
2022 Medicare Part D:
•99 percent of people with a
•31 percent of people with a
•$7.40 is the lowest monthly premium for a
Enhanced Alternative plans may offer additional gap coverage which is calculated as the percentage of generic formulary products with coverage above standard "generic" coverage gap cost-sharing benefit and/or the percentage of brand formulary products covered in addition to the coverage gap discount for applicable drugs.GAP
In 2022 once you and your plan provider have spent $4430 on covered drugs. (combined amount plus your deductible) You will be in the coverage gap. (AKA "donut hole") Once you reach the coverage gap you will pay 25% of the plans cost for covered brand-name prescription drugs and 25% on generic drugs unless your plan offers additional coverage. You will also receive discounted prescription drugs.Full LIS
Plans that offer Full Low Income Subsidy (also called Extra Help). The amount of Extra Help a beneficiary receives depends on their income and resources. Most people who qualify for Full Low Income Subsidy will pay no premiums or deductibles and pay no more than the LIS drug coverage cost limit.
Plans as of September 1, 2021.
Plans are subject to change as contracts are finalized.
Includes 2022 approved contracts/plans. Employer sponsored 800 series plans and plans under sanction are excluded. For 2022, enhanced alternative plans may offer additional cost sharing reductions in the gap on a sub-set of the formulary drugs, beyond the standard Part D benefit.